![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Direct-to-Consumer Program for Diabetes, Migraine, Weight-Loss Drugs Launched by Lilly
Direct-to-Consumer Program for Diabetes, Migraine, Weight-Loss Drugs Launched by Lilly
In a move that sidesteps pharmacy benefit managers, Eli Lilly has launched a direct-to-consumer marketing program that will provide several of the company’s medicines for obesity, migraine, and diabetes at steeply discounted prices, and without the need for a face-to-face doctor visit.
LillyDirect will allow patients to order 14 medications for home delivery. Twelve of these are various types of insulin, all which are capped at $35 per month. The program also includes the weight loss drug Zepbound (tirzepatide) and one migraine medication, Emgality (galcenezumab).
The move comes just as the company launches a public service campaign against using the GLP-1 inhibitor and other Lilly weight-loss drugs simply for cosmetic purposes.
To read the whole story, click here to subscribe.
Related Topics
Upcoming Events
-
11Jul
-
18Jul
-
21Oct